Mrna Flu

• The FDA has approved mFlusiva, marking the first time an mRNA-based vaccine has been authorized for the prevention of influenza. • Unlike traditional flu vaccines, mRNA technology allows manufacturers to produce shots more rapidly, reducing the likelihood of a mismatch between the vaccine and circulating strains. • Medical experts, including Dr. Paul Pottinger of UW Medical Center, describe the approval as a significant advancement in public health.

• The FDA has approved Moderna's new mRNA-based flu vaccine, named mFlusiva, which is specifically intended for adults aged 50 and older. • This approval marks a shift toward using mRNA technology for seasonal influenza, moving away from traditional egg-based vaccine production methods. • The development is significant as it aims to provide more precise and potentially more effective protection against evolving flu strains.

• The FDA approved mFlusiva, the first mRNA-based flu vaccine developed by Moderna, on Wednesday. • The vaccine is approved for adults aged 50 to 65 and those 65 and older, with late-stage trials showing it is approximately 27% more effective than standard flu shots. • This approval is significant as it applies the same messenger RNA platform used in Pfizer and Moderna's COVID-19 vaccines to seasonal influenza.

• The U.S. FDA has approved Moderna's first mRNA-based influenza vaccine specifically for adults aged 50 and older. • This decision follows a reversal of a previous refusal and leverages mRNA technology that was rapidly accelerated and proven safe during the COVID-19 pandemic. • The approval is significant as it expands the use of mRNA technology to combat seasonal diseases, while Health Canada is currently considering its own approval of the shot.

• Health officials have approved mFLUSIVA, the first mRNA-based flu vaccine developed by Moderna, which is expected to be available by the next flu season. • Clinical data indicates the shot may be 27% more effective than traditional vaccines, though side effects like fatigue and headaches occurred in up to two-thirds of patients. • The rollout follows a severe winter flu season characterized by a virulent strain that led to record-high case numbers across multiple US states.

• The FDA has approved the first mRNA-based flu vaccine, developed by Moderna, specifically for adults aged 50 and older. • Former FDA vaccine regulator Jesse Goodman noted the shot's documented superiority in effectiveness over standard doses for the 50-64 age group, particularly those with underlying health conditions. • The new vaccine serves as a potent alternative for seniors 65 and over and will be covered by Medicare, according to KFF health policy expert Jennifer Kates.

• The FDA has approved mFlusiva, the first mRNA-based influenza vaccine developed by Moderna, specifically targeting adults aged 50 and older. • The regulatory strategy includes full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, pending a postmarketing study using a high-dose comparator. • This approval follows a unanimous recommendation from the FDA’s Vaccines and Related Biological Products Advisory Committee in June 2026.

• The FDA has approved Moderna's mFLUSIVA, the first seasonal influenza vaccine utilizing mRNA technology to receive official authorization. • The vaccine is specifically approved for use in adults aged 50 and older, marking a significant milestone for the drugmaker's mRNA platform. • This approval is critical as it demonstrates the potential for mRNA technology to address broader public health challenges beyond COVID-19.

The mFlusiva vaccine for older people is first made with mRNA platform key to ending coronavirus pandemicThe Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic, Moderna, the manufacturer, said.The shot, named mFlusiva, is intended for adults aged 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late on Wednesday that it expected some of its new version to be available soon at select retailers. Continue reading...

• The FDA has approved Moderna’s mFlusiva, marking the first time a licensed influenza vaccine has been developed using messenger RNA (mRNA) technology. • This approval represents a significant milestone for mRNA, a platform that gained global prominence during the COVID-19 pandemic but has faced scrutiny from vaccine skeptics. • The shift to mRNA for flu shots is critical because the technology allows for faster production and potentially better matching to evolving seasonal virus strains.

Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and olderUS health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic.Moderna is seeking Food and Drug Administration (FDA) approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Continue reading...